Quantum Genomics Société Anonyme (ALQGC.PA)
EUR 0.07
(0.0%)
EUR 0.07
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.13 Million EUR | 89.57% |
| 2022 | -30.08 Million EUR | -49.57% |
| 2021 | -20.11 Million EUR | -19.49% |
| 2020 | -16.83 Million EUR | -56.43% |
| 2019 | -10.75 Million EUR | 20.87% |
| 2018 | -13.59 Million EUR | -32.12% |
| 2017 | -10.29 Million EUR | -65.57% |
| 2016 | -6.21 Million EUR | -44.22% |
| 2015 | -4.31 Million EUR | -78.28% |
| 2014 | -2.41 Million EUR | -27.07% |
| 2013 | -1.9 Million EUR | -79.33% |
| 2012 | -1.06 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.12 Million EUR | 0.0% |
| 2023 Q4 | -1.14 Million EUR | 0.0% |
| 2023 FY | -3.15 Million EUR | 89.52% |
| 2023 Q2 | -2 Million EUR | 0.0% |
| 2022 Q4 | -20.45 Million EUR | 0.0% |
| 2022 Q2 | -12.85 Million EUR | 0.0% |
| 2022 FY | -30.08 Million EUR | -49.57% |
| 2021 FY | -20.11 Million EUR | -19.49% |
| 2021 Q4 | -9.91 Million EUR | 0.0% |
| 2021 Q2 | -7.56 Million EUR | 0.0% |
| 2020 FY | -16.83 Million EUR | -56.43% |
| 2020 Q2 | -5.95 Million EUR | 0.0% |
| 2020 Q4 | -8.72 Million EUR | 0.0% |
| 2019 FY | -10.75 Million EUR | 20.87% |
| 2019 Q2 | -5.32 Million EUR | 0.0% |
| 2019 Q4 | -5.43 Million EUR | 0.0% |
| 2018 Q4 | -6.78 Million EUR | 0.0% |
| 2018 FY | -13.59 Million EUR | -32.12% |
| 2018 Q2 | -6.81 Million EUR | 0.0% |
| 2017 Q2 | -4.5 Million EUR | 0.0% |
| 2017 FY | -10.29 Million EUR | -65.57% |
| 2017 Q4 | -5.79 Million EUR | 0.0% |
| 2016 FY | -6.21 Million EUR | -44.22% |
| 2016 Q4 | -3.14 Million EUR | 0.0% |
| 2016 Q2 | -3.07 Million EUR | 0.0% |
| 2015 Q4 | -2.37 Million EUR | 0.0% |
| 2015 FY | -4.31 Million EUR | -78.28% |
| 2015 Q2 | -1.93 Million EUR | 0.0% |
| 2014 Q2 | -1.36 Million EUR | 0.0% |
| 2014 Q4 | -1.05 Million EUR | 0.0% |
| 2014 FY | -2.41 Million EUR | -27.07% |
| 2013 Q3 | -475.85 Thousand EUR | 50.9% |
| 2013 Q1 | -475.85 Thousand EUR | 0.0% |
| 2013 Q2 | -969.17 Thousand EUR | -103.67% |
| 2013 Q4 | -933.36 Thousand EUR | -96.15% |
| 2013 FY | -1.9 Million EUR | -79.33% |
| 2012 Q3 | -264.67 Thousand EUR | 0.0% |
| 2012 Q1 | -264.67 Thousand EUR | 0.0% |
| 2012 FY | -1.06 Million EUR | 0.0% |
| 2012 Q4 | -475.85 Thousand EUR | -79.79% |
| 2012 Q2 | -264.67 Thousand EUR | 0.0% |
| 2011 Q4 | -264.67 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | 8.052% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 97.537% |
| Adocia SA | -17.62 Million EUR | 82.197% |
| Aelis Farma SA | -6.46 Million EUR | 51.443% |
| Biophytis S.A. | -14.33 Million EUR | 78.112% |
| Advicenne S.A. | -6.45 Million EUR | 51.413% |
| genOway Société anonyme | 2.06 Million EUR | 251.903% |
| IntegraGen SA | -183.77 Thousand EUR | -1607.163% |
| Medesis Pharma S.A. | -4.22 Million EUR | 25.822% |
| Neovacs S.A. | -6.9 Million EUR | 54.582% |
| NFL Biosciences SA | -4.43 Million EUR | 29.188% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -303.123% |
| Sensorion SA | -22.31 Million EUR | 85.938% |
| Theranexus Société Anonyme | -7.64 Million EUR | 58.956% |
| TME Pharma N.V. | -5.62 Million EUR | 44.217% |
| Valbiotis SA | -7.16 Million EUR | 56.184% |
| TheraVet SA | -2.17 Million EUR | -44.234% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 84.536% |
| argenx SE | -417.15 Million EUR | 99.248% |
| BioSenic S.A. | -7.04 Million EUR | 55.437% |
| Celyad Oncology SA | -8.45 Million EUR | 62.903% |
| DBV Technologies S.A. | -85.24 Million EUR | 96.32% |
| Galapagos NV | -88.26 Million EUR | 96.446% |
| Genfit S.A. | -26.58 Million EUR | 88.197% |
| GeNeuro SA | -14.35 Million EUR | 78.149% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 80.384% |
| Innate Pharma S.A. | -12.66 Million EUR | 75.237% |
| Inventiva S.A. | -102.7 Million EUR | 96.945% |
| MaaT Pharma SA | -19.94 Million EUR | 84.269% |
| MedinCell S.A. | -20.97 Million EUR | 85.044% |
| Nanobiotix S.A. | -26.77 Million EUR | 88.285% |
| Onward Medical N.V. | -35.46 Million EUR | 91.153% |
| Oryzon Genomics S.A. | -4.54 Million EUR | 31.037% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 86.351% |
| Oxurion NV | -12.11 Million EUR | 74.094% |
| Pharming Group N.V. | -4.87 Million EUR | 35.706% |
| Poxel S.A. | -28.76 Million EUR | 89.093% |
| GenSight Biologics S.A. | -29.69 Million EUR | 89.435% |
| Transgene SA | -30.01 Million EUR | 89.547% |
| Financière de Tubize SA | -2.14 Million EUR | -46.329% |
| UCB SA | 604 Million EUR | 100.519% |
| Valneva SE | -82.08 Million EUR | 96.178% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 89.121% |